login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
BRIACELL THERAPEUTICS -CW27 (BCTXW) Stock News
USA
- NASDAQ:BCTXW -
0.0578
USD
+0 (+2.3%)
Last: 10/24/2025, 12:20:47 PM
Overview
Stock Chart
Technical Analysis
News
BCTXW Latest News, Press Relases and Analysis
All
Press Releases
2 days ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
3 days ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study
3 days ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer
4 days ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025
11 days ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025
21 days ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting
2 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal
2 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer
2 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Announces Proposed Effective Date of Share Consolidation
2 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer
3 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Announces Proposed Effective Date of Share Consolidation
3 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study
3 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Awarded New Zealand Patent for its Whole Cell Technology
3 months ago - By: BriaCell Therapeutics Corp.; BriaPro Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents
3 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025
3 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Therapeutics Announces Closing of $15 million Public Offering
3 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Therapeutics Announces Pricing of $15 million Public Offering
3 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer
4 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer
4 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient
4 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study
4 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer
4 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven
4 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer
5 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26
5 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025
5 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor
5 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025
5 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell CEO Letter to Shareholders
6 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified
6 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Therapeutics Announces Closing of $13.8 million Public Offering
6 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development
6 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering
6 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™
6 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Announces Four Clinical Data Presentations at ASCO 2025
6 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)
6 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer
7 months ago - By: BriaCell Therapeutics Corp.
- Mentions:
BCT.CA
BCTX
BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference
Please enable JavaScript to continue using this application.
